Varex Imaging Corp Q3 FY2025 Earnings: Revenue Surpasses Estimates at $203M, Non-GAAP EPS at $0.18, Medical Segment Revenue Down 4% YoY
ByAinvest
Wednesday, Aug 13, 2025 3:09 pm ET1min read
VREX--
The company's Medical segment saw a 4% decrease in revenue to $142 million, while the Industrial segment experienced a slight increase of 1% to $61 million. Despite the overall revenue decline, the company's performance is noteworthy as it surpassed the high-end of its guidance, driven by strong performance in the Industrial segment and better-than-expected Medical revenue in China [2].
Varex Imaging Corp achieved a non-GAAP gross margin of 34%, up from 32% in the same quarter last year. The non-GAAP net earnings per diluted share increased to $0.18, surpassing the analyst estimate of -$0.12. These achievements are significant for a company in the Medical Devices & Instruments industry, as they reflect operational efficiency and the ability to maintain profitability despite revenue challenges [1].
However, the company reported a GAAP net loss of $2.15 per diluted share, primarily due to a $93.9 million impairment of goodwill. Cash flow from operations was $8 million, and cash, cash equivalents, and marketable securities totaled $153 million at the end of the quarter, down from $226 million in the previous quarter. This decrease was mainly due to the repayment of Convertible Notes [1].
Looking ahead, Varex Imaging Corp expects revenues between $210 million and $230 million for the fourth quarter of fiscal year 2025, with non-GAAP net earnings per diluted share projected to be between $0.10 and $0.30. This guidance reflects the company's anticipation of continued demand in both the Medical and Industrial segments [1].
References:
[1] https://www.gurufocus.com/news/3046889/varex-imaging-corp-q3-fy2025-earnings-revenue-surpasses-estimates-at-203m-nongaap-eps-at-018
[2] https://www.tradingview.com/news/tradingview:abbb1226f5fe3:0-varex-imaging-corporation-announces-q3-fy2025-financial-results/
Varex Imaging Corp reported Q3 FY2025 revenue of $203M, surpassing estimates, but declining 3% YoY. The Medical segment saw a 4% decrease, while the Industrial segment increased 1%. The company achieved a non-GAAP gross margin of 34%, up from 32% last year, and a non-GAAP net earnings per diluted share of $0.18, surpassing the analyst estimate of -$0.12. However, the company reported a GAAP net loss of $2.15 per diluted share due to a $93.9M impairment of goodwill.
Varex Imaging Corp (VREX) has released its unaudited financial results for the third quarter of fiscal year 2025, reporting a revenue of $203 million, which surpassed analyst estimates of $190.32 million. However, this figure represents a 3% decline year-over-year (YoY) from the same quarter last year [1].The company's Medical segment saw a 4% decrease in revenue to $142 million, while the Industrial segment experienced a slight increase of 1% to $61 million. Despite the overall revenue decline, the company's performance is noteworthy as it surpassed the high-end of its guidance, driven by strong performance in the Industrial segment and better-than-expected Medical revenue in China [2].
Varex Imaging Corp achieved a non-GAAP gross margin of 34%, up from 32% in the same quarter last year. The non-GAAP net earnings per diluted share increased to $0.18, surpassing the analyst estimate of -$0.12. These achievements are significant for a company in the Medical Devices & Instruments industry, as they reflect operational efficiency and the ability to maintain profitability despite revenue challenges [1].
However, the company reported a GAAP net loss of $2.15 per diluted share, primarily due to a $93.9 million impairment of goodwill. Cash flow from operations was $8 million, and cash, cash equivalents, and marketable securities totaled $153 million at the end of the quarter, down from $226 million in the previous quarter. This decrease was mainly due to the repayment of Convertible Notes [1].
Looking ahead, Varex Imaging Corp expects revenues between $210 million and $230 million for the fourth quarter of fiscal year 2025, with non-GAAP net earnings per diluted share projected to be between $0.10 and $0.30. This guidance reflects the company's anticipation of continued demand in both the Medical and Industrial segments [1].
References:
[1] https://www.gurufocus.com/news/3046889/varex-imaging-corp-q3-fy2025-earnings-revenue-surpasses-estimates-at-203m-nongaap-eps-at-018
[2] https://www.tradingview.com/news/tradingview:abbb1226f5fe3:0-varex-imaging-corporation-announces-q3-fy2025-financial-results/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet